85 related articles for article (PubMed ID: 25079575)
1. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
2. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
[TBL] [Abstract][Full Text] [Related]
3. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
Zhang C; Liu R; Gao B; Li T; Wang H; Song T; Ma Y; Xu W; Liu Y; Zhang X; Tian DC; Yang C; Shi K
J Neuroimmunol; 2024 Feb; 387():578285. PubMed ID: 38219400
[TBL] [Abstract][Full Text] [Related]
5. Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.
Cacciaguerra L; Tortorella P; Rocca MA; Filippi M
Neurotherapeutics; 2021 Jul; 18(3):1623-1636. PubMed ID: 33909234
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica - an update: 2007-2009.
Jacob A
Ann Indian Acad Neurol; 2009 Oct; 12(4):231-7. PubMed ID: 20182570
[TBL] [Abstract][Full Text] [Related]
7. CD11c
Amano E; Sato W; Kimura Y; Kimura A; Lin Y; Okamoto T; Sato N; Yokota T; Yamamura T
Neurol Neuroimmunol Neuroinflamm; 2024 Mar; 11(2):e200206. PubMed ID: 38350043
[TBL] [Abstract][Full Text] [Related]
8. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
Tallantyre EC; Whittam DH; Jolles S; Paling D; Constantinesecu C; Robertson NP; Jacob A
J Neurol; 2018 May; 265(5):1115-1122. PubMed ID: 29511864
[TBL] [Abstract][Full Text] [Related]
9. B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20.
Levy M; Mealy MA
Immunotargets Ther; 2021; 10():325-331. PubMed ID: 34447723
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
Gonzalez Caldito N; Graham EL; Grebenciucova E
Mult Scler; 2024 Feb; 30(2):272-274. PubMed ID: 38116592
[TBL] [Abstract][Full Text] [Related]
11. Development of RISS in two patients with NMOSD undergoing rituximab treatment: a case report.
Ersöz AS; Yaşargün DÖ; Mısırlı CH
Acta Neurol Belg; 2024 Jun; 124(3):1041-1042. PubMed ID: 37904077
[No Abstract] [Full Text] [Related]
12. Targeting B cells in neuromyelitis optica spectrum disorder.
Zhang C; Shi FD
Lancet Neurol; 2024 Jun; 23(6):549-550. PubMed ID: 38760085
[No Abstract] [Full Text] [Related]
13. Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.
Farhat L; Dara J; Duberstein S; De A
Drug Saf Case Rep; 2018 May; 5(1):22. PubMed ID: 29752554
[TBL] [Abstract][Full Text] [Related]
14. Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
Sawaya R; Saab G; Moussa H
Neurologia (Engl Ed); 2020 Nov; ():. PubMed ID: 33176917
[No Abstract] [Full Text] [Related]
15. Naïve B cells followed by aquaporin-4 antibodies characterise the onset of neuromyelitis optica: evidence from stem cell transplantation.
McNaughton P; Payne R; Michael S; Leahy T; Nicols A; Fower A; Hambleton S; Pang K; Gennery A; Irani SR
J Neurol Neurosurg Psychiatry; 2022 May; 93(11):1234-6. PubMed ID: 35606107
[No Abstract] [Full Text] [Related]
16. Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children.
Longoni G; Banwell B; Filippi M; Yeh EA
Neurol Neuroimmunol Neuroinflamm; 2014 Dec; 1(4):e46. PubMed ID: 25520954
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the treatment of neuromyelitis optica.
Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
